National and Kapodistrian University of Athens
Retrospective registration and prospective study: rheumatoid arthritis and interstitial lung disease: natural history, clinical features, diagnosis, outcome and response to treatment
Abstract
dc:descriptionBackground: Rheumatoid arthritis (RA) is a systemic inflammatory disorder that affects an estimated 0.5-1% of the population in the USA and northern European countries. Lung involvement is the most common extra-articular manifestation of RA, which can affect up to 60% of patients during the disease course. Interstitial lung disease (ILD) mainly affects lung parenchyma commonly guiding to lung fibrosis and is a significant cause of morbidity and mortality in rheumatoid arthritis (RA). Early recognition of RA-ILD is associated with early therapeutic intervention and prevention of lung fibrosis. Identified risk factors for the development of ILD in patients with RA, include among others high disease activity, seropositivity for rheumatoid factor and/or anti–cyclic citrullinated peptide (anti-CCP), and polymorphisms in MUC5B. However, ILD can still develop in the absence of these factors suggesting that the pathophysiological processes leading to pulmonary injury need to be further explored. RNA sequencing (RNA-seq) of peripheral blood may provide an unbiased and detailed look at pathogenetic events involved. Objective: To explore the natural history and prognostic factors of RA-ILD in a contemporary patient cohort and investigate underlying pathogenetic events via RNA-seq of peripheral blood, to analyze the clinical and laboratory characteristics of these patients, to calculate mortality rate of RA-ILD in the ‘Attikon’ cohort and evaluate the impact of comorbidities and different ILD radiographic patterns on mortality. Methods: Retrospective chart review was performed to analyze the clinical, laboratory and radiological characteristics of patients with RA-ILD. Patients were enrolled consecutively from September 2020 to December 2023, if they fulfilled the following inclusion criteria: i) 2010 ACR/EULAR classification criteria for RA (20), ii) ILD diagnosed by high-resolution CT (HRCT) at baseline, iii) available data on modified Medical Research Council (mMRC) Dyspnea Scale, iv) available data on Pulmonary Function Tests (PFTs), including Forced Vital Capacity (FVC) and Diffusing Capacity for CO corrected (DLCOcSB), and v) available follow-up data on HRCT (yearly), mMRC and PFTs. For each patient, the first visit to the unit and registration in the cohort is defined as the enrollment visit. Data recorded included comorbidities, changes in pulmonary function tests, radiological pattern of lung involvement and complications during the follow-up period. Key outcomes included mortality, clinical progression through Modified Medical Research Council (mMRC) Dyspnea scale, and radiological progression. To compare survival time and time to progression between patients’ subgroup, Kaplan-Meier curves and log-rank test were used. Multivariable Cox models were used to identify predictors for progression and death, adjusting for confounders. Peripheral blood was collected from a subset of RA-ILD (n=11/81), RA non-ILD (n=10), psoriatic arthritis (PsA n=23) and healthy controls (HC, n= 7) for transcriptomics analysis. Patients were divided into subgroups based on autoantibodies’ profile, HRCT pattern and ILD progression (progressors vs non-progressors) for further transcriptomic analysis. The gene expression profile of RA-ILD was inferred through differential gene expression analysis followed by pathway and enrichment analysis. Publicly available data from patients with systemic sclerosis-related ILD were explored to define an ‘ILD-signature’. Drug repurposing analysis was performed to identify perturbagens that counteract RA-ILD-specific signatures. Results: We included 81 RA-ILD patients with a median (IQR) follow-up of 3.6 years (1.6-5.1). Median disease duration from ILD diagnosis was 4.3 years (IQR 2.4-5.9). Seropositive RA was observed in two thirds of patients (n=54/81, 67%). Non-specific interstitial pneumonia (NSIP) was the most frequent radiologic pattern (64%). Patients with usual interstitial pneumonia (UIP) exhibited significantly worse survival compared to NSIP/OP (organizing pneumonia) patients (NSIP/OP vs UIP, HR for death: 0.29, p 0.01). ILD progressed clinically in 28 patients (35%) and radiologically in eight patients (9.9%). RF and/or ACPA negativity was an independent risk factor for ILD progression (seropositive vs seronegative, HR for progression: 0.44, p:0.02). Transcriptomic analysis of peripheral blood distinguished the RA-ILD group from the RA group. In RA-ILD patients, differential expression analysis revealed enrichment in immune response pathways (humoral immune response, macrophage activation, myeloid mediated immunity and differentiation), metabolism (Oxphos, hypoxia), cytokine activation and extracellular matrix. An ILD signature emerged, consisting of pathways related to metabolism, extracellular matrix, IFNγ response and response to microorganisms. Pathway analysis of different radiologic subsets signatures showed that fNSIP is characterized by antigen processing and presentation, dendritic cell differentiation and endocytic vesicles; non-UIP is characterized by immunoglobulin complex; and UIP by humoral immune response, neutrophil mediated immunity, phagocytosis and complement activation. Differential expression analysis of clinical and/or radiological progressors versus non-progressors revealed enriched pathways related to cell cycle, DNA replication, IFNγ response, inflammasome assembly and negative regulation of immune response in progressors. Drug repurposing revealed that ITK, Syk and FAK inhibitors are promising compounds to reverse the transcriptomic signature of progression. Conclusion: In a contemporary RA-ILD cohort, NSIP is the most frequent radiologic pattern, but UIP confers a significantly increased mortality risk. Seronegativity seems to be an independent risk factor for disease progression. RA-ILD patients exhibit enhanced immune responses, metabolism and cytokine activation, while universal ILD signature is characterized by pathways related to metabolism and response to microorganisms. fNSIP is characterized by antigen processing and presentation, dendritic cell differentiation and endocytic vesicles; non-UIP (NSIP/OP) is characterized by immunoglobulin complex; and UIP by humoral immune response, neutrophil mediated immunity, phagocytosis and complement activation. Progressive disease is characterized by enriched pathways related to cell cycle, DNA replication, IFNγ response, inflammasome assembly and negative regulation of immune response. ITK, Syk and FAK inhibitors may be promising compounds for the reversal of the transcriptomic signature of progression.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Flouda, Sofia
- Φλούδα, Σοφία
Subjects
dc:subject × 16- Ρευματοειδής αρθρίτιδα
- Διάμεση πνευμονοπάθεια
- Μεταγραφομική ανάλυση
- Θνητότητα
- Πρόοδος νόσου
- Rheumatoid arthritis
- Interstitial lung disease
- Transcriptomic analysis
- Mortality
- Disease progression
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ρευματολογία
- Clinical Medicine
- Medical and Health Sciences
- Rheumatology
Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/61962